Celltrion Acquires Eli Lilly’s New Jersey Plant: A Strategic Move into the U.S. Market
On Tuesday, Celltrion Inc., the South Korean biosimilar powerhouse, announced its agreement to acquire Eli Lilly and Company’s manufacturing plant located in Branchburg, New Jersey, for approximately 460 billion won (around $330 million). This pivotal acquisition marks a significant milestone for Celltrion, as it establishes its first manufacturing base in the United States, a strategic move catalyzed by concerns over potential tariffs on imported pharmaceuticals.
Financial Commitment and Expansion Plans
Celltrion is embarking on an extensive financial journey related to this acquisition. The initial outlay for operational funds is projected to total around 700 billion won. Furthermore, the company intends to invest an additional 700 billion won for expansion and upgrades, leading to a staggering total investment of roughly 1.4 trillion won. This ambitious financial commitment underscores Celltrion’s dedication to enhancing its manufacturing capabilities in the U.S. market.
Chairman Seo Jung-jin expressed optimism about the company’s financial forecast, stating that he expects earnings before interest, taxes, depreciation, and amortization (EBITDA) to reach about 3 trillion won next year. This anticipated growth provides a strong foundation for financing the plant acquisition and further investments.
The Branchburg Plant: Features and Production Capacity
The facility in New Jersey spans 150,000 square meters (approximately 37 acres) and includes four dedicated buildings encompassing manufacturing, research and development (R&D), and storage facilities. Notably, there is also additional space available for expansion on 36,000 square meters of vacant land. Once Celltrion completes its planned expansions, the Branchburg plant is projected to have a production capacity approximately 1.5 times greater than Celltrion’s current second plant in Incheon, Korea, which has a capacity of 90,000 liters.
The acquisition presents Celltrion with an immediate production base in the U.S. at a fraction of the cost compared to constructing a new facility. This proactive step not only mitigates the risk of future tariffs on Korean-made drugs but also establishes a localized supply chain for production and marketing.
Addressing Tariff Risks
Over the past few years, Celltrion has faced escalating warnings from Washington regarding potential import duties that could reach as high as 250% on foreign-made medicines. This looming threat has prompted the company to take preemptive measures, including shipping two years’ worth of inventory to the U.S. market and engaging with local contract manufacturers. By acquiring the New Jersey plant, Celltrion efficiently alleviates these tariff risks and gains a foothold in one of the world’s most lucrative pharmaceutical markets.
Chairman Seo noted, “With this U.S. plant acquisition, we have saved about 1.5 trillion won by eliminating tariff risks and avoiding the cost of building a new facility.” This strategic maneuver not only secures production capacity but also helps retain skilled talent within the United States.
Operational Transition and Future Production Plans
In the immediate aftermath of the acquisition, Celltrion and Eli Lilly plan to extend their partnership to ensure a smooth transition of operations. Celltrion will retain all current employees at the Branchburg site, thereby maintaining production continuity for Eli Lilly’s products. Under the terms of the acquisition, the plant will continue producing biologic medicines for Eli Lilly for the next five years while also integrating Celltrion’s biosimilars into its production lines.
Looking towards the future, the plant is set to support Celltrion’s entire U.S. product lineup after a validation period of 12 to 18 months. Chairman Seo revealed that Celltrion intends to utilize half of the plant’s production lines for Eli Lilly’s products while planning to introduce its own products by 2027. This includes key offerings like the autoimmune therapies Zymfentra and Yuflyma, alongside the oncology drug Vegzelma.
Broader Strategic Implications
The acquisition also reflects Celltrion’s broader strategy to enhance its competitive edge in the global pharmaceutical landscape. Currently, about 30% of the company’s revenue is sourced from the U.S., and it aims to increase this share by leveraging its expanded manufacturing footprint. The move towards a local manufacturing base is a critical response to ongoing concerns about U.S. trade policies, particularly as the company has been actively monitoring tariff rates since earlier this year.
Conclusion on Company Operations and Future Initiatives
With federal regulatory approvals pending, Celltrion’s U.S. subsidiary is expected to finalize the plant purchase by year-end. This acquisition may lead Celltrion to reconsider earlier plans for constructing a fourth facility in South Korea, as Chairman Seo emphasized that U.S. tariffs are a pressing concern for the company. The Branchburg operation promises seamless production capabilities, and as the partnership with Eli Lilly continues, both companies are well-poised to thrive amidst a rapidly changing pharmaceutical landscape.
In summary, this strategic acquisition empowers Celltrion to bolster its operations, mitigate tariff risks, and enhance its market position in the United States. As the company moves forward, the integration of this facility into its operations will play a crucial role in shaping its future success in the global biosimilar market.